Source: Annual Congress 2002 - COPD - general -3
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. E. Makarevich (Minsk, Belarus). Pyrogenal plus aprotinin therapy of COPD patients with immune reactivity depression. Eur Respir J 2002; 20: Suppl. 38, 1680

Member's Comments

No comment yet.

Related content which might interest you: Immunological effectiveness of N-acetylcystein in complex therapy in severe persistent bronchial asthma patients Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Effectiveness of prolonged cholinolytic in complex basic therapy on the tolerability of physical load in severe bronchial asthma patients Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008 Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 674s Year: 2006 Burden of disease among exacerbating patients with eosinophil COPD treated with triple therapy in Spain Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Immunological effectiveness of atorvastatin in complex therapy of severe persistent bronchial asthma Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Compliance with nebulized therapy in patients with chronic lung disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Diagnosis and treatment of COPD patients who respond to steroids  Source: International Congress 2017 – State of the art session: "Airway diseases" Year: 2017